Rangeley Capital, LLC Bridge Bio Pharma, Inc. Transaction History
Rangeley Capital, LLC
- $111 Billion
- Q4 2024
A detailed history of Rangeley Capital, LLC transactions in Bridge Bio Pharma, Inc. stock. As of the latest transaction made, Rangeley Capital, LLC holds 5,000 shares of BBIO stock, worth $159,750. This represents 0.12% of its overall portfolio holdings.
Number of Shares
5,000Holding current value
$159,750% of portfolio
0.12%Shares
1 transactions
Others Institutions Holding BBIO
# of Institutions
303Shares Held
170MCall Options Held
10.5MPut Options Held
2.37M-
Kohlberg Kravis Roberts & Co. L.P. New York, NY25.3MShares$807 Million35.94% of portfolio
-
Viking Global Investors LP25.1MShares$803 Million2.47% of portfolio
-
Vanguard Group Inc Valley Forge, PA15.1MShares$482 Million0.01% of portfolio
-
Black Rock Inc. New York, NY12.4MShares$398 Million0.01% of portfolio
-
Aisling Capital Management LP New York, NY6.07MShares$194 Million61.0% of portfolio
About BridgeBio Pharma, Inc.
- Ticker BBIO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 148,246,000
- Market Cap $4.74B
- Description
- BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include AG10 and BBP-265, a small molecule stabili...